Industry Analysis Medical & Healthcare

Sales Value of Recombinant Human Thrombopoietin Reached CNY 1257 Million in China

In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver diseases and tumor chemotherapy. Thrombopenia may also be congenital or drug induced. Primary immune thrombopenia is a clinically common hemorrhagic disease, accounting for 1/3 of hemorrhagic diseases. The annual incidence of primary immune thrombopenia is 5/100,000 to 10/100,000. The number of patients with thrombopenia in China is increasing by over 100,000 every year. Research shows…

Read More